- Home » News and Events
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Catalent Launches New Service for End-to-End Supply Chain Case Management of Cell and Gene Therapies
Jan 24, 2023
The new Case Management Service addresses challenges associated with delivering advanced therapies to patients by providing supply chain oversight from program start to finish.
Catalent Appoints Ricardo Zayas as North American Biologics Operations Leader
Jan 17, 2023
Mr. Zayas will be responsible for Catalent’s North American biologics operations. He will serve on the Executive Leadership Team, reporting directly to President & CEO, Alessandro Maselli.
Sarepta and Catalent Expand Strategic Manufacturing Partnership
Jan 5, 2023
Catalent and Sarepta sign an agreement to manufacture delandistrogene moxeparvovec, Sarepta’s most advanced gene therapy candidate for the treatment of Duchenne muscular dystrophy.
Catalent to Expand Its Biologics Analytical Services with New Facility in Durham, North Carolina
Dec 14, 2022
The new facility within North Carolina’s Research Triangle, will offer comprehensive analytical development and testing for biologic drug modalities.
Catalent Opens One of the World’s Largest Commercial-Scale Cell Therapy Manufacturing Facilities at its European Center of Excellence for Cell Therapies in Gosselies, Belgium
Dec 8, 2022
The new facility will be one of the largest in the world with multi-product, segregated suites designed to support autologous and allogeneic cell therapy manufacturing.
Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline
Nov 3, 2022
The ADC candidates have been developed using Catalent’s proprietary SMARTag® technology.
Catalent Expands Biologics Analytical Capabilities with New Laboratories at Center of Excellence in Kansas City, Missouri
Oct 20, 2022
Catalent today announced a $12 million expansion program to increase biologics CGMP analytical capabilities at its flagship facility in Kansas City, Missouri.
Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study
Jul 7, 2022
Xenetic Biosciences today announced it has entered into a manufacturing agreement with Catalent, which will include cGMP manufacturing for the recombinant protein, Human DNase I.
Catalent Launches UpTempo Virtuoso™ AAV Platform to Reduce Gene Therapy Development Time and Accelerate Path to Clinic
May 16, 2022
The UpTempo Virtuoso platform streamlines many time-consuming steps in AAV manufacturing to significantly reduce the timeline from gene to clinic and enable rapid first-in-human clinical evaluation.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.